Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Maximilian F Konig¹, Alfred Hj Kim^{2

3

4}, Marc H Scheetz^{5

6}, Elizabeth R Graef⁷, Jean W Liew⁸, Julia Simard⁹, Pedro M Machado^{10

11

12}, Milena Gianfrancesco¹³, Jinoos Yazdany¹³, Daman Langguth¹⁴, Philip C Robinson¹⁵; COVID-19 Global Rheumatology Alliance

Affiliations

¹ Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.
² Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
³ Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
⁴ Andrew M. and Jane M. Bursky Center of Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, Missouri, USA.
⁵ Departments of Pharmacy Practice and Pharmacology; Pharmacometrics Center of Excellence, Midwestern University, Chicago College of Pharmacy, and College of Graduate Studies, Downers Grove, Illinois, USA.
⁶ Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
⁷ Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
⁸ Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
⁹ Department of Epidemiology & Population Health; Department of Medicine, Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, California, USA.
¹⁰ Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.
¹¹ Department of Rheumatology & Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK.
¹² Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.
¹³ Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
¹⁴ Department of Immunology, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia.
¹⁵ The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.

PMID: 32381561
PMCID: PMC8258626
DOI: 10.1136/annrheumdis-2020-217690

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Maximilian F Konig et al. Ann Rheum Dis. 2020 Oct.

. 2020 Oct;79(10):1386-1388.

doi: 10.1136/annrheumdis-2020-217690. Epub 2020 May 7.

Authors

Affiliations

¹ Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.
² Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
³ Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
⁴ Andrew M. and Jane M. Bursky Center of Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, Missouri, USA.
⁵ Departments of Pharmacy Practice and Pharmacology; Pharmacometrics Center of Excellence, Midwestern University, Chicago College of Pharmacy, and College of Graduate Studies, Downers Grove, Illinois, USA.
⁶ Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
⁷ Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
⁸ Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA.
⁹ Department of Epidemiology & Population Health; Department of Medicine, Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, California, USA.
¹⁰ Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.
¹¹ Department of Rheumatology & Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK.
¹² Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.
¹³ Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
¹⁴ Department of Immunology, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia.
¹⁵ The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.

PMID: 32381561
PMCID: PMC8258626
DOI: 10.1136/annrheumdis-2020-217690

No abstract available

Keywords: epidemiology; hydroxychloroquine; lupus erythematosus, systemic; pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MFK received personal fees from Bristol-Myers Squibb and Celltrion, unrelated to this manuscript. AHK received personal fees from Exagen Diagnostics, Inc and GlaxoSmithKline, unrelated to this manuscript. PMM received personal fees from Abbvie, Eli Lilly, Novartis and UCB Pharma. JY received personal fees from Astra Zeneca and Eli Lilly, unrelated to this manuscript. PCR reports personal fees from Abbvie, Pfizer, UCB Pharma, Novartis, Eli Lilly and Janssen, and non-financial support from Roche.

Comment in

Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
Carbillon L, Benbara A, Boujenah J. Carbillon L, et al. Ann Rheum Dis. 2021 Apr;80(4):e54. doi: 10.1136/annrheumdis-2020-217847. Epub 2020 May 31. Ann Rheum Dis. 2021. PMID: 32475831 No abstract available.
Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al.
Konig MF, Gianfrancesco M, Yazdany J, Robinson PC. Konig MF, et al. Ann Rheum Dis. 2021 Apr;80(4):e55. doi: 10.1136/annrheumdis-2020-217990. Epub 2020 May 31. Ann Rheum Dis. 2021. PMID: 32475834 Free PMC article. No abstract available.
Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France.
Sbidian E, Penso L, Herlemont P, Botton J, Baricault B, Semenzato L, Drouin J, Weill A, Dray-Spira R, Zureik M. Sbidian E, et al. Ann Rheum Dis. 2023 May;82(5):e117. doi: 10.1136/annrheumdis-2020-218647. Epub 2020 Aug 28. Ann Rheum Dis. 2023. PMID: 32859610 No abstract available.

References

1. AHJ K, Sparks JA, Liew JW, et al. A rush to judgment? rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med 2020:M20–1223. - PMC - PubMed
1. Lane JCE, Weaver J, Kostka K, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. Rheumatology 2020.
1. Roden DM, Harrington RA, Poppas A, et al. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. J Am Coll Cardiol 2020. doi: 10.1016/j.jacc.2020.04.016. [Epub ahead of print: 09 Apr 2020]. - DOI - PMC - PubMed
1. Chorin E, Dai M, Shulman E, et al. The QT interval in patients with SARS-CoV-2 infection treated with Hydroxychloroquine/Azithromycin. Cardiovascular Medicine 2020.
1. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Epidemiology 2020.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

L30 AR072421/AR/NIAMS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Affiliations

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Authors

Affiliations

Conflict of interest statement

Comment in

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous